#Athe hashtag - Bluesky

韓国ブランドATHEが阪急うめだで成功のオフラインPOP-UPを開催 韓国のバッグブランド「ATHE」が阪急うめだ本店で初のオフラインPOP-UPストアを展開。フレンチシックなスタイルをお楽しみください。

1 month ago

韓国ブランドATHEが阪急うめだで成功のオフラインPOP-UPを開催 #バッグ #athe #RUBAN

韓国のバッグブランド「ATHE」が阪急うめだ本店で初のオフラインPOP-UPストアを展開。フレンチシックなスタイルをお楽しみください。

0 0 0 0

パリの感性が息づく韓国ブランド「ATHE」が初のオフラインポップアップを開催 韓国の人気ブランドATHEが、阪急うめだ本店で日本初のオフラインポップアップを実施。フレンチシックなバッグやアクセサリーに出会えるチャンスです。

1 month ago

パリの感性が息づく韓国ブランド「ATHE」が初のオフラインポップアップを開催 #大阪府 #大阪市 #ポップアップ #阪急うめだ #athe

韓国の人気ブランドATHEが、阪急うめだ本店で日本初のオフラインポップアップを実施。フレンチシックなバッグやアクセサリーに出会えるチャンスです。

0 0 0 0

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 Alterity Therapeutics (NASDAQ: ATHE) reported that its Phase 2 program of ATH434 in multiple system atrophy (MSA) produced "resoundingly favourable" results, showing safety comparable to placebo with no drug-related serious or severe adverse events and signals of slowed disease progression across functional, mobility, and orthostatic hypotension measures. The company plans an End-of-Phase 2 meeting with the FDA in mid-2026 to finalise Phase 3 design and is scaling clinical, manufacturing, and regulatory resources. Other 2025 actions include appointing Julian Babarczy as Board Chair and strengthening investor relations and corporate strategy teams. Management cites an estimated $2.4 billion market opportunity for MSA.

2 months ago

#ATHE Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

ReligionsKill

@religionskill.bsky.social

4 months ago

"There Is No God. This negation must be understood solely to affect a creative Deity. The hypothesis of a pervading Spirit co-eternal with the universe remains unshaken."
— Percy Bysshe Shelley, Queen Mab, Canto VII, Note 13
#Athe...
#atheism #atheist #religion #faith #god

👉 Vote!

2 0 0 0

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report Alterity Therapeutics (NASDAQ: ATHE) released its Q1 FY26 Appendix 4C and program update for the quarter ended 30 September 2025. Key items: cash A$54.56M and operating cash outflows of A$5.34M for the quarter; A$20M gross raised via a strategic placement.Clinical highlights include a strengthened efficacy signal for ATH434 75 mg (−2.8 UMSARS I points; 35% relative effect at 52 weeks), positive open‑label ATH434‑202 results with brain volume preservation, biomarker target engagement, and peer‑reviewed neuroimaging publication. An independent commercial assessment estimates a USD $2.4B peak sales opportunity in MSA. FDA Type C meetings and an End‑of‑Phase 2 meeting are planned, with the EOP2 expected mid‑2026.

5 months ago

#ATHE Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders – Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker analysis advance understanding of MSA diagnosis – MELBOURNE, Australia and SAN

5 months ago

#ATHE Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

First Potential Treatment for MSA: Alterity's ATH434 Phase 2 Results Show Disease Progression Slowdown Alterity Therapeutics will present Phase 2 clinical trial data for ATH434 in Multiple System Atrophy at MDS Congress 2025, featuring oral and poster presentations on disease progression outcomes.

6 months ago

#ATHE Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

ReligionsKill

@religionskill.bsky.social

6 months ago

Climpson's carked it. Was beginning to feel a bit sad, til near the end it said he was a skyfairydelusionist. Oh well, fuck off then Roger, you're dead to me. At least, that's what... Brian told me. #RogerClimpson #Athe...

Climpson's carked it.
Was beginning to feel a bit sad, til near the end it said he was a skyfairydelusionist. Oh well, fuck off then Roger, you're dead to me. At least, that's what... Brian told me.
#RogerClimpson #Athe...
#atheism #atheist #religion #faith #god

👉 Vote!

0 0 0 0

Disease-Modifying Success: Alterity's ATH434 Drug Shows Meaningful Efficacy in Rare Brain Disease Trial Alterity's ATH434 demonstrated efficacy in slowing Multiple System Atrophy progression at 50mg and 75mg doses, with positive safety profile. Data presented at ANA conference shows reduced disease severity.

6 months ago

#ATHE Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

The Blind Guy

@blindcoder.bsky.social

6 months ago

I am spawning a new website for Crypto news. Using the same technology, with a short 7 long Magazine page. Those will remain password-protected w/subscription by SCRT coin.
#athe #crypto

1 0 0 0

Neurodegenerative Drug Developer Alterity Raises A$20M After Promising Multiple System Atrophy Results Biotech firm Alterity secures A$20M placement at 7.7% discount following successful Phase 2 trials of ATH434 for Multiple System Atrophy. Funds to advance FDA regulatory pathway.

6 months ago

#ATHE Alterity Therapeutics Raises A$20.0 million in Strategic Placement

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

Market Wire News

@marketwirenews.com

8 months ago

Just In: ( NASDAQ: #ATHE ) Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

1 0 0 0

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy Alterity Therapeutics (NASDAQ: ATHE) announced positive topline data from its ATH434-202 open-label Phase 2 clinical trial for treating Multiple System Atrophy (MSA). The trial demonstrated that ATH434 reduced disease progression by approximately 50% compared to historical controls over 12 months, as measured by the Modified Unified MSA Rating Scale Part I.Key findings include: 30% of participants reported stable neurological symptoms, stabilization of orthostatic hypotension symptoms, and slowed brain atrophy in MSA-affected areas. The drug showed a favorable safety profile with no serious adverse events related to treatment. Importantly, these results were consistent with the company's previous double-blind Phase 2 trial (ATH434-201), supporting the advancement of ATH434 in MSA treatment.

8 months ago

#ATHE Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study Alterity Therapeutics (NASDAQ: ATHE) has announced the publication of a groundbreaking study in the Annals of Clinical and Translational Neurology, introducing the MSA Atrophy Index (MSA-AI), a novel MRI-based measurement tool for Multiple System Atrophy (MSA).The research, developed through Alterity's bioMUSE Natural History Study, employs deep learning methods to track brain atrophy in MSA patients. The study demonstrated that MSA-AI can effectively distinguish MSA from related conditions like Parkinson's disease and Dementia with Lewy Bodies, with significantly lower scores indicating reduced brain volumes in MSA patients (p Importantly, the study revealed that 12-month brain volume reductions correlated with clinical disease worsening. This innovative tool will be implemented in Alterity's Phase 2 clinical program and future Phase 3 trials for patient selection and disease progression monitoring.

8 months ago

#ATHE Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

韓国ヴィーガンコスメ「athé」大阪で新商品を体験するイベントレポート 韓国のヴィーガンコスメブランド「athé」が、大阪の@cosme OSAKAで新商品の体験イベントを開催しました。参加者の声や今後の展開もご紹介！

8 months ago

韓国ヴィーガンコスメ「athé」大阪で新商品を体験するイベントレポート #美容液 #ヴィーガンコスメ #athe

韓国のヴィーガンコスメブランド「athé」が、大阪の@cosme OSAKAで新商品の体験イベントを開催しました。参加者の声や今後の展開もご紹介！

0 0 0 0

韓国ヴィーガンコスメ「athé」の大阪ポップアップイベントが大盛況！ 韓国のヴィーガンコスメブランド「athé」が@cosme OSAKAで開催したポップアップイベントの模様をお伝えします。新商品の体験やお客様の声を紹介！

8 months ago

韓国ヴィーガンコスメ「athé」の大阪ポップアップイベントが大盛況！ #大阪府 #大阪市 #ヴィーガンコスメ #大阪イベント #athe

韓国のヴィーガンコスメブランド「athé」が@cosme OSAKAで開催したポップアップイベントの模様をお伝えします。新商品の体験やお客様の声を紹介！

0 0 0 0

Alterity Therapeutics to Provide Corporate Update in Fireside Chat Alterity Therapeutics (NASDAQ: ATHE) has announced that CEO David Stamler will participate in a Fireside Chat hosted by MST Access on June 25, 2025 (Australia) / June 24, 2025 (US). The presentation will focus on providing updates regarding the company's ATH434 development program in Multiple System Atrophy, following the release of positive Phase 2 data in January. The webcast will take place at 9:00 a.m. AEST for Australian participants and 4:00 p.m. PT / 7:00 p.m. ET for US participants. Registration is required for attendance, and a recording will be made available on the company's website.

9 months ago

#ATHE Alterity Therapeutics to Provide Corporate Update in Fireside Chat

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

韓国ヴィーガンコスメ「athé」が大阪でPOP UPイベント開催！新商品も登場 韓国のヴィーガンコスメブランド「athé」が、大阪で7日間限定のPOP UPイベントを開催。新商品や特典も盛りだくさん！

9 months ago

韓国ヴィーガンコスメ「athé」が大阪でPOP UPイベント開催！新商品も登場 #POP_UP #ヴィーガンコスメ #athe

韓国のヴィーガンコスメブランド「athé」が、大阪で7日間限定のPOP UPイベントを開催。新商品や特典も盛りだくさん！

0 0 0 0

韓国の新しいヴィーガンコスメ「athé」が大阪でポップアップ開催 韓国のヴィーガンコスメブランド「athé」は、大阪の@cosme OSAKAでポップアップイベントを開催。新商品や体験も充実しています。

9 months ago

韓国の新しいヴィーガンコスメ「athé」が大阪でポップアップ開催 #大阪府 #大阪市 #ヴィーガン #韓国コスメ #athe

韓国のヴィーガンコスメブランド「athé」は、大阪の@cosme OSAKAでポップアップイベントを開催。新商品や体験も充実しています。

1 0 0 0

韓国ヴィーガンコスメ「athé」の初のオフラインイベントが大盛況！ 韓国のヴィーガンコスメブランド「athé」の大阪万博におけるオフラインイベントが盛況に閉幕。多くの人気商品が完売し、新商品も注目を集めました。

10 months ago

韓国ヴィーガンコスメ「athé」の初のオフラインイベントが大盛況！ #韓国コスメ #大阪万博 #athe

韓国のヴィーガンコスメブランド「athé」の大阪万博におけるオフラインイベントが盛況に閉幕。多くの人気商品が完売し、新商品も注目を集めました。

0 0 0 0

韓国ヴィーガンコスメ「athé」の展示会が大盛況！大阪万博に登場 韓国のヴィーガンコスメブランド「athé」が大阪万博での展示会を開催。多くの来場者が訪れ、新商品が完売する大盛況のイベントとなりました。

10 months ago

韓国ヴィーガンコスメ「athé」の展示会が大盛況！大阪万博に登場 #大阪府 #大阪市 #大阪万博 #ヴィーガンコスメ #athe

韓国のヴィーガンコスメブランド「athé」が大阪万博での展示会を開催。多くの来場者が訪れ、新商品が完売する大盛況のイベントとなりました。

1 0 0 0

Alterity Therapeutics Prominently Featured at the International MSA Congress Alterity Therapeutics (NASDAQ: ATHE) presented significant findings at the 2025 International MSA Congress regarding their ATH434 Phase 2 clinical trial and related MSA research. The ATH434-201 trial demonstrated promising results, with the 50mg dose showing a 48% relative treatment effect (p=0.02) and the 75mg dose showing a 30% effect (p=0.16) in reducing disease severity on the UMSARS I scale. The drug was well-tolerated with no serious adverse events.Key research presentations included the development of the MSA Atrophy Index (MSAai), a new imaging biomarker for improved MSA diagnosis and monitoring, and findings from the bioMUSE Natural History Study showing increased α-synuclein levels in skin correlating with greater orthostatic symptoms. The study also demonstrated ATH434's ability to stabilize or reduce iron accumulation in affected brain regions and showed trends in reducing brain atrophy at both dose levels.

10 months ago

#ATHE Alterity Therapeutics Prominently Featured at the International MSA Congress

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

大阪万博で体験！athéの新感覚スキンケアで光る肌を目指そう 大阪万博で期間限定発売されるathéの新しいスキンケア商品を紹介。7日間の集中ケアで美白効果を実感！

10 months ago

大阪万博で体験！athéの新感覚スキンケアで光る肌を目指そう #スキンケア #大阪万博 #athe

大阪万博で期間限定発売されるathéの新しいスキンケア商品を紹介。7日間の集中ケアで美白効果を実感！

0 0 0 0

新感覚スキンケア！athé（アッテ）が美容施術並みの効果を実現 韓国のヴィーガンコスメブランド「athé（アッテ）」が、大阪万博で新商品「メレーザープログラミング AP」を期間限定発売。自宅で美容施術を体験できる魅力を紹介します。

10 months ago

新感覚スキンケア！athé（アッテ）が美容施術並みの効果を実現 #大阪府 #大阪市 #スキンケア #大阪万博 #athe

韓国のヴィーガンコスメブランド「athé（アッテ）」が、大阪万博で新商品「メレーザープログラミング AP」を期間限定発売。自宅で美容施術を体験できる魅力を紹介します。

0 0 0 0

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress Alterity Therapeutics (NASDAQ: ATHE) announced multiple presentations at the 2025 International MSA Congress in Boston, highlighting their clinical programs in Multiple System Atrophy (MSA). The company will present Phase 2 data for ATH434, their lead candidate that recently received Fast Track Designation from the FDA. Dr. David Stamler, CEO, will deliver a plenary presentation on how "ATH434 Slowed Disease Progression in Phase 2 Study." The congress will also feature research from Vanderbilt University Medical Center collaborators on MSA biomarkers. ATH434 is an oral agent designed to inhibit pathological protein aggregation in neurodegeneration by restoring brain iron balance. The drug has shown positive results in Phase 2 trials, demonstrating clinical efficacy, target engagement, and favorable safety. ATH434 has received both FDA and European Commission Orphan Drug Designation for MSA treatment.

10 months ago

#ATHE Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

Breakthrough: FDA Fast-Tracks Novel MSA Drug ATH434 - First Potential Treatment for Fatal Brain Disease Latest FDA designation accelerates development of ATH434 for rare neurological disorder MSA. See how this breakthrough could address critical unmet medical need.

10 months ago

#ATHE Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium Alterity Therapeutics (NASDAQ: ATHE) presented Phase 2 clinical trial results for ATH434-201 at the MSA Research Symposium. The double-blind study, involving 71 patients, demonstrated significant efficacy in treating Multiple System Atrophy (MSA).Key findings include:48% relative treatment effect at 50mg dose (p=0.02) and 30% at 75mg dose (p=0.16) on UMSARS I scaleImprovement in Clinical Global Impression of Severity Scale at both dosesEnhanced patient mobility metrics including step count and walking timePositive results in reducing brain atrophy and stabilizing iron levels in affected brain regionsThe treatment was well-tolerated with similar adverse event rates to placebo, with no serious adverse events attributed to ATH434. The strong clinical efficacy data and novel mechanism support continued advancement of ATH434 for MSA treatment.

11 months ago

#ATHE Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

www.stocktitan.net/news/ATHE/alterity-thera...

0 0 0 0